Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843283 | 0.89 | LMNA (0.45) | LMNAPOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL4840569 | 0.80 | MMP8 (0.45) | POLBMAPTALDH1A1 | |
| SCHEMBL4838439 | 0.78 | MMP8 (0.44) | MAPTALDH1A1 | |
| SCHEMBL4838046 | 0.77 | MMP8 (0.42) | LMNAPOLBALDH1A1 | |
| SCHEMBL4843008 | 0.76 | MMP8 (0.41) | LMNAMAPTALDH1A1 | |
| SCHEMBL4833588 | 0.76 | MMP8 (0.41) | MAPTALDH1A1TDP1 | |
| SCHEMBL4842412 | 0.76 | MAPT (0.43) | LMNAMAPTALDH1A1 | |
| SCHEMBL928146 | 0.76 | LMNA (0.52) | LMNAMAPTKDM4EALDH1A1CYP1A2 | |
| SCHEMBL4837853 | 0.75 | MCL1 (0.42) | MAPTKDM4EALDH1A1 | |
| SCHEMBL4843172 | 0.75 | RORC (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | LMNA 1809/4885POLB 3286/4885MAPT 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.